Drug Combination Details
| General Information of the Combination (ID: C56247) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Trastuzumab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Phase 1 | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| BT-483 | CVCL_2319 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-453 | CVCL_0418 | Breast adenocarcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergy between flavopiridol and trastuzumab can result from enhanced apoptosis, and that combination effects on EGFR expression are involved in the interaction. | |||||
